After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients

After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients
Mateon Therapeutics announced that it is immediately ending the FOCUS trial of CA4P to treat platinum-resistant ovarian cancer, based on disappointing interim results. The results showed that CA4P (fosbretabulin) did not significantly improve progression-free survival in patients receiving CA4P plus standard of care with Avastin (bevacizumab) and chemotherapy. FOCUS was a Phase 2/3 clinical trial (NCT02641639) that

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *